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We sought to obtain novel insights into schizo-
phrenia pathogenesis by exploiting the association
between the disorder and chromosomal copy num-
ber (CNV) burden. We combined data from 5,745
cases and 10,675 controls with other published
datasets containing genome-wide CNV data. In this
much-enlarged sample of 11,355 cases and 16,416
controls, we show for the first time that case CNVs
are enriched for genes involved in GABAergic neuro-
transmission. Consistent with non-genetic reports
of GABAergic deficits in schizophrenia, our findings
now show disrupted GABAergic signaling is of direct
causal relevance, rather than a secondary effect or
due to confounding. Additionally, we independently
replicate and greatly extend previous findings of
CNV enrichment among genes involved in glutama-
tergic signaling. Given the strong functional links
between the major inhibitory GABAergic and excit-
atory glutamatergic systems, our findings converge
on a broad, coherent set of pathogenic processes,
providing firm foundations for studies aimed at dis-
secting disease mechanisms.
INTRODUCTION
Schizophrenia is a highly heritable disorder (Cardno and Gottes-
man, 2000), the genetic architecture of which includes a large
number of alleles spanning the full spectrum of frequencies (Sul-
livan et al., 2012). It has been estimated that the additive effects
of common variation, as indexed by alleles represented on the
platforms used in genome-wide association studies (GWASs),
contribute around a quarter to a third of the total population vari-ance in schizophrenia liability. However, the 108 genome-wide-
associated common variant loci reported in the largest GWAS
study to date only explain a small fraction of this contribution
(Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014). An increased burden of rare mutations
has also been documented in schizophrenia, taking the form of
both large CNVs (International Schizophrenia Consortium,
2008; Rees et al., 2014b; Walsh et al., 2008) and single-nucleo-
tide variants (SNVs) (Purcell et al., 2014), which often occur as de
novomutations (Kirov et al., 2012; Malhotra et al., 2011; Xu et al.,
2008). While several CNVs have been implicated in the disorder,
no individual SNV has yet been robustly associated (Purcell et al.,
2014). The CNVs (n = 11) strongly associated with schizophrenia
in the largest systematic survey to date (Rees et al., 2014b) are in
general large in both size (> 500 kb) and effect (ORs 2–60), the
latter being in stark contrast with the small effects conferred
by common alleles (typical OR < 1.1). Approximately 2.5% of
patients and 0.9% of unaffected controls carry a CNV that is
strongly supported as a risk factor for schizophrenia (Rees
et al., 2014b). The pathogenic effects of these CNVs are not
confined to schizophrenia; many increase risk for other disorders
with a putative major neurodevelopmental component such as
intellectual disability, autism spectrum disorder, and attention
deficit hyperactivity disorder (Girirajan et al., 2012; Malhotra
and Sebat, 2012; Williams et al., 2010).
A small number of single-gene CNVs have been associated
with schizophrenia, but the only ones to be definitively implicated
are deletions of NRXN1 (Kirov et al., 2008; Rees et al., 2014b),
which encodes the presynaptic cell adhesion protein neurexin
1. All other robustly associated CNVs span multiple genes mak-
ing it difficult to infer the biological mechanism(s) through which
they contribute to disease. Nevertheless, early pathway or gene
set analyses of schizophrenia case-control CNV datasets indi-
cated that case CNVs were enriched for synaptic and neurode-
velopmental genes (Glessner et al., 2010; Walsh et al., 2008).
It has been noted that these initial approaches to pathway
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size (Raychaudhuri et al., 2010). However, a study of parent-pro-
band trios in which these factors were taken into account found
that de novo CNVs in people with schizophrenia were enriched
for synaptic proteins (Kirov et al., 2012). Moreover, this was
largely the result of enrichment for genes encoding members
of N-methyl-D-aspartate receptor (NMDAR) (Husi and Grant,
2001; Husi et al., 2000; Pocklington et al., 2006) and neuronal ac-
tivity-regulated cytoskeleton-associated (ARC) protein com-
plexes, both of which are known to be important for synaptic
plasticity and cognitive function in rodents. When these same
sets were additionally examined in large case-control datasets,
case CNVs were found to contain an excess of genes from
NMDAR, but not ARC, complexes (Kirov et al., 2012; Szatkiewicz
et al., 2014). Exome sequencing studies have subsequently sup-
ported a role for both NMDAR and ARC complexes in disease
(Fromer et al., 2014; Purcell et al., 2014). The same exome
sequencing studies also found evidence of enrichment for rare
disruptive and de novo point mutations among targets of fragile
X mental retardation protein (FMRP) (Darnell et al., 2011), a
finding that has also been reported for CNVs in a large schizo-
phrenia case-control study (Szatkiewicz et al., 2014).
Here we present a detailed functional analysis of the largest
schizophrenia CNV dataset for which full autosomal CNV data
have been examined to date. The study is based on 11,355
cases and 16,416 controls from three separate studies: the Inter-
national Schizophrenia Consortium (ISC), the Molecular Ge-
netics of Schizophrenia (MGS), and a UK study of individuals
diagnosed with schizophrenia and taking the anti-psychotic
clozapine (CLOZUK) (International Schizophrenia Consortium,
2008; Levinson et al., 2011; Rees et al., 2014b). The ISC and
MGS datasets were utilized in Kirov et al. (2012) to investigate
CNV enrichment for ARC and NMDAR gene sets, while no
CNV gene set analyses have yet been performed in CLOZUK.
Starting from the hypothesis that schizophrenia reflects pertur-
bation of brain function and development, our primary analysis
focuses on a circumscribed set of annotations that are related
to CNS function and development and are based on proteomic,
RNA sequencing, and functional genetic data. In order to eval-
uate to what extent the pathogenic effects of CNVs primarily
reflect disruption of brain function, as a secondary analysis we
searched more widely for additional gene set enrichments using
amore comprehensive range of annotations available from large,
freely accessible databases.
RESULTS
We identified 134 gene sets relevant to various aspects of ner-
vous system function and development, covering subcellular
neuronal function, cellular physiology, cell morphology, brain re-
gion and fiber tract morphology, behavior, and brain develop-
ment (Table S1). Gene sets were derived from functional studies
of single genes recorded in the MGI Mammalian Phenotype (MP)
database (Blake et al., 2014) with the exception of subcellular
neuronal terms, which comprised a mixture of CNS-related
gene sets taken from previous studies of schizophrenia (Fromer
et al., 2014; Kirov et al., 2012; Purcell et al., 2014) as well as sets
that were curated from the proteomic literature (see Table S1 for
full list of references). To constrain multiple testing, we utilized a1204 Neuron 86, 1203–1214, June 3, 2015 ª2015 The Authorssubset of the terms available from MGI (Table S1), which repre-
sented CNS annotations postulated to be of most likely rele-
vance to schizophrenia, while at the same time retaining broad
functional coverage to allow for the emergence of novel patho-
physiological clues. Directional terms such as ‘‘decreased’’ or
‘‘enhanced’’ were avoided in favor of broader categories de-
noted by ‘‘abnormal,’’ ‘‘impaired,’’ etc.
CNV Enrichment in Gene Sets with Strong Prior
Evidence for Involvement in Schizophrenia
Consistent with recent approaches (Szatkiewicz et al., 2014),
our analyses are based on large, rare CNVs (> 100 kb, fre-
quency < 1%), as these are both the most robustly called and
most enriched in people with schizophrenia. Gene set enrich-
ment analysis was performed using a logistic regression model
(Kirov et al., 2012) with covariates included to control for the
size and total number of genes overlapping each CNV and for
the source of the data (study and genotyping array used). As
we were only interested in gene sets that were enriched for
CNVs in cases, we used one-tailed tests.
Of the 134 CNS-related gene sets, we first evaluated those for
which there existed prior, replicated evidence of enrichment for
rare mutations in schizophrenia in at least three independent
studies: the NMDAR protein network, ARC protein complex,
andmRNA targets of FMRP. Here, as in all subsequent analyses,
we first tested for enrichment in the combined set of CNVs and
then deletions and duplications separately. The results of these
analyses were Bonferroni corrected for the nine tests performed.
NMDAR network genes were highly enriched in CNVs overall
(Pcorrected = 3.823 10
8), the signal primarily coming from dupli-
cations (Pcorrected = 2.263 10
8). The ARC gene set was not en-
riched for CNVs overall, but was enriched in the secondary test of
deletions (Pcorrected = 0.0031), while FMRP targets displayed a
modest trend toward enrichment in deletions (Pcorrected = 0.076).
Both ISC andMGS samples were utilized in our previous study
(Kirov et al., 2012) to investigate CNV enrichment for ARC and
NMDAR. We therefore asked whether we would have found
the above NMDAR and ARC association signals if we had per-
formed our analysis in CLOZUK only. Restricting to CLOZUK
samples, case CNVs were still enriched for both NMDAR
network (Pcorrected = 1.5 3 10
6 combined, Pcorrected = 7.8 3
107 duplications) and ARC (Pcorrected = 0.0077 deletions) gene
sets. Thus, our analysis provides fully independent evidence
for the NMDAR network and ARC complexes.
Large CNVs Disrupt an Excess of CNS Gene Sets in
Schizophrenia
We next investigated CNV enrichment for the full list of 134 CNS-
related gene sets. To evaluate whether there was evidence for
a general enrichment of CNS gene sets in our data, we tested
whether the numbers of sets surpassing defined enrichment
p value thresholds (Puncorrected < 0.01, 0.001) were greater than
expected. To do this, gene set enrichments for the full set of
134 CNS-related terms were compared to those generated
from permuted data in which CNVs were randomly re-assigned
among individuals, with the constraint that assignments were
restricted to individuals from the same study so we could
continue to allow for chip and study effects. In our analysis of
Table 1. Enrichment of CNS Gene Sets for Association Signal
Ncase Nctrl
Significance Threshold
0.01 0.001
Nexp Nobs p Padj Nexp Nobs p Padj
All 8,139 10,469 1.3 23 < 0.001 < 0.006 0.2 13 < 0.001 < 0.006
Deletion 3,164 4,234 1.4 38 < 0.001 < 0.006 0.2 25 < 0.001 < 0.006
Duplication 4,975 6,235 1.4 14 0.004 0.024 0.2 10 0.001 0.006
All (minus known loci) 7,649 10,028 1.3 10 0.015 0.03 0.1 4 0.005 0.01
Deletion (minus known loci) 2,963 4,140 1.4 11 0.008 0.048 0.1 2 0.024 0.14
Duplication (minus known loci) 4,856 6,165 1.4 6 0.038 0.23 0.1 3 0.006 0.036
The number of CNS gene sets with association p value surpassing a pre-defined threshold (p < 0.01 or 0.001) was compared to that seen in permuted
data (1,000 permutations of CNV case-control status). Columns list the number of case and control CNVs contributing to each analysis (Ncase and Nctrl,
respectively); the average number of gene sets with p value surpassing a given threshold in the permuted data, Nexp; the actual number of gene sets
surpassing the same threshold in the unpermuted data, Nobs; the empirical probability of finding Nobs or more gene sets surpassing the p value
threshold in the permuted data, p; and the Bonferroni-corrected probability, Padj. Results are given for the combined analysis of all CNVs and for
the analysis of deletions and duplications separately; these are presented first for the full dataset and then for the subset of CNVs that do not overlap
well-supported schizophrenia loci.deletions and duplications combined, more sets were enriched
for CNVs in schizophrenia than expected under the null at all
enrichment p value thresholds. This was also truewhen deletions
and duplications were considered separately (Table 1).
To evaluate the significance of the tests of individual gene sets
in a manner that allows easy comparison with our later analyses
of the much larger annotation datasets (where permutation tests
were computationally prohibitive), we adjusted gene set p values
for multiple testing using Bonferroni correction for the 402 CNS
gene set tests (134 sets 3 3 analyses) performed (Table S1).
Recognizing that this is over-conservative due to annotation
overlap, in Table 2 we additionally list all gene sets with an uncor-
rected p < 0.001 under the combined test of all CNVs. As can be
seen from Table 1, given the large excess in the observed num-
ber of associated sets compared with expectation (minimum
Nobs/Nexp = 50), most gene sets surpassing this threshold are
likely to be true positives, even if they do not survive correction
for multiple testing here. Functional processes captured by the
six terms with a Bonferroni-corrected p value < 0.05 centered
upon behavioral and physiological correlates of learning and
related neuronal complexes.
For the combined analysis of all CNVs, after the NMDAR
complex (Pcorrected = 1.71 3 10
6) the next most highly associ-
ated term was the GABAA receptor complex (Pcorrected =
0.0012). Conditional analyses revealed these two signals to be
essentially independent (see conditional analysis of GO and
MGI below; see also Supplemental Experimental Procedures).
Thus not only do we confirm, as noted above, the involvement
of proteins involved in plasticity of the major excitatory system
of the CNS, we also provide the first strong genetic evidence
for an etiological role in the disorder for proteins affiliated with
the major inhibitory system in the CNS, namely GABAA receptor
complexes (Heller et al., 2012).
Deletions and Duplications Independently Enriched in
CNS Gene Sets
Tables 3 and 4 list all gene sets with Puncorrected < 0.001 for
enrichment within deletions and duplications, respectively. AfterBonferroni correction for the 402 CNS gene set tests, there were
14 terms with p value < 0.05 for enrichment in case deletions and
7 terms for case duplications. Enrichment for duplications was
largely confined to behavioral and subcellular neuronal gene
sets; terms associated via deletions extended over behavior,
cellular physiology, subcellular complexes, and development.
Deletions were most highly enriched for components of PSD-
95 protein complexes (Ferna´ndez et al., 2009). PSD-95, a major
postsynaptic scaffolding protein at glutamatergic synapses, in-
teracts with a wide range of channels and receptors including
NMDARs. It is notable that although the NMDAR and PSD-95
complexes are functionally related and have overlapping
membership, the observations of strong (ORs > 3) and highly
significant enrichments (both Pcorrected < 10
7) for these sets
relate to duplications and deletions, respectively. These find-
ings are therefore based on sets of completely independent
CNVs and, as such, provide extremely robust support for an
etiological role for the disruption of glutamatergic signaling in
schizophrenia.
Disruption of CNS Gene Sets Extends beyond Known
Schizophrenia Loci
Current data provide strong support for 11 CNV loci in schizo-
phrenia: 6 deletions and 5 duplications (Rees et al., 2014b)
(Table S2). Removing CNVs overlapping these known loci, we
re-calculated CNS gene set enrichment. Deletion, duplication,
and combined analyses all retained an excess of associated
terms (Table 1); of the 14 gene sets enriched for deletions, 5
remained nominally associated (Puncorrected < 0.05) when known
loci were removed, as did 5 of the 7 terms enriched for duplica-
tions (Table S3).
Individual Genes within Associated Gene Sets
To identify genes contributing most to gene set enrichment we
calculated single gene association p values. This was done in
the same manner as our gene set enrichment analyses, but
with each ‘‘set’’ restricted to a single gene. For each CNS term
with a Bonferroni-corrected p value < 0.05 we then extractedNeuron 86, 1203–1214, June 3, 2015 ª2015 The Authors 1205
Table 2. Enriched CNS Gene Sets, Combined Analysis
Ngene
Combined Deletion Duplication
p Padj OR (95% CI) p Padj p Padj
NMDAR network 59 4.33109 1.73106 2.47 (1.8–3.44) 0.045 1 2.53109 1.03106
GABAA 15 3.0310
6 0.0012 2.51 (1.65–3.97) 0.00068 0.27 5.43105 0.022
Abnormal associative learning 193 1.63105 0.0066 1.38 (1.19–1.61) 1.0 1 1.631010 6.23108
Abnormal long-term potentiation 145 2.03105 0.0081 1.49 (1.24–1.8) 0.58 1 1.13106 0.00044
Abnormal behavior 1,973 5.13105 0.020 1.12 (1.06–1.19) 3.03106 0.0012 0.05 1
Abnormal CNS synaptic transmission 371 5.53105 0.022 1.22 (1.11–1.35) 5.13106 0.002 0.12 1
Thin cerebral cortex 45 0.00018 0.071 1.91 (1.32–2.8) 0.12 1 0.0006 0.24
Abnormal consumption behavior 442 0.00019 0.077 1.24 (1.09–1.41) 0.059 1 0.0005 0.2
Abnormal cued conditioning behavior 68 0.00027 0.11 1.69 (1.24–2.35) 0.55 1 1.43105 0.0055
Abnormal synaptic transmission 437 0.00027 0.11 1.18 (1.08–1.29) 1.13105 0.0044 0.21 1
Abnormal learning/memory/conditioning 424 0.00031 0.12 1.18 (1.08–1.29) 7.33105 0.029 0.089 1
PSD-95 (core) 58 0.00048 0.19 1.71 (1.28–2.28) 4.331011 1.73108 0.97 1
Abnormal contextual conditioning behavior 89 0.00061 0.24 1.53 (1.18–1.99) 0.52 1 0.00011 0.045
CNS gene sets with Puncorrected < 0.001 in the combined analysis of deletions and duplications are listed along with the number of genes in each set,
Ngene; uncorrected (p) and Bonferroni-corrected (Padj) p values for enrichment in case CNVs; estimated odds ratios (OR); and p values for enrichment in
case deletions and duplications when analyzed separately. Note that while the NMDAR network was analyzed prior to other terms in this table, here it is
corrected for the same number of tests as other terms for ease of comparison. See also Tables S1 and S3.all genes with an uncorrected single gene p value < 0.05 (Tables
S4, S5, and S6). To obtain significance at the level of an individ-
ual gene, there must be multiple observations of CNVs at the
same region. It is therefore unsurprising that established recur-
rent CNV risk loci account for many such findings. Moreover,
as recurrent CNVs are large, these frequently overlap multiple
genes and contribute to multiple sets (e.g., del22q11; Table
S5). It should be noted that some CNVs also hit multiple genes
within a single set, but as each CNV only contributes once to
the regression model (see Experimental Procedures), co-locali-
zation of set members does not inflate the significance of the
set-based enrichment. A number of nominally associated genes
lying outside established loci are well known to be important for
neuronal signaling. These include the glutamate transporter
SLC1A1, a recently reported candidate CNV locus for schizo-
phrenia (Myles-Worsley et al., 2013; Rees et al., 2014a);
GABAergic (GABRD also reported in Rees et al., 2014a) and
nicotinic receptors (CHRNA4); synaptic scaffolding proteins
DLG2, DLGAP1, and SHANK2; and key elements of the presyn-
aptic vesicle release machinery PCLO and NSF.
Some of the nominally associated genes have been linked
to Mendelian disorders with neurological symptoms, including
Walker-Warburg syndrome, a congenital muscular dystrophy
with brain and eye abnormalities (ISPD OMIM: 614643, POMK
OMIM: 615249); nocturnal frontal lobe epilepsy type 1 (CHRNA4
OMIM: 600513); generalized epilepsy (GABRD OMIM: 613060);
spastic paraplegia 51, an autosomal recessive developmental
disorder with severe intellectual disability (AP4E1 OMIM:
613744); and Batten disease, an autosomal recessive neurode-
generative condition (CLN3 OMIM: 204200).
No Evidence for Gene Set Enrichment beyond CNS
We next determined whether any other gene sets had evidence
for enrichment in case CNVs that was independent of the asso-1206 Neuron 86, 1203–1214, June 3, 2015 ª2015 The Authorsciation signal captured by our primary CNS-related terms. For
this we drew upon both the MGI MP database (Blake et al.,
2014), from which we had derived most of our CNS-related
gene sets, and the widely used Gene Ontology (GO) terms (Ash-
burner et al., 2000). As the MP database contains an extensive
range of physiological, behavioral, and morphological pheno-
types, but little of the low-level molecular function annotation
present in GO, these two classifications are to an extent non-
redundant and complementary.
We first identified a ‘‘minimal set’’ of terms capturing most of
the enrichment signal arising from CNS-related gene sets. Tak-
ing the CNS terms surviving Bonferroni correction, we added
the most significant term as a covariate to the regression model
and recalculated gene set enrichment for each of the remaining
terms. The term with the most significant residual enrichment
was then added to the model, and the process repeated until
there was no residual association (Puncorrected < 0.05) in the re-
maining CNS annotations. Three terms were required to capture
CNS gene set enrichment in the combined analysis of duplica-
tions and deletions: NMDAR network, GABAA receptor complex,
and abnormal behavior (see Supplemental Experimental Proce-
dures). This indicates that there are independent enrichment sig-
nals in the NMDAR network and GABAA receptor complex gene
sets, as reported above. Conditioning on the above three CNS
terms, no other GO or MP term survived Bonferroni correction
(Tables S7 and S8).
CNS gene set enrichment for deletions was captured by
three terms: PSD-95 complex, abnormal fear/anxiety-related
behavior, and abnormal neural plate morphology (see Supple-
mental Experimental Procedures). Conditioning on these terms,
noMP or GO term survived Bonferroni correction (Tables S7 and
S8). Three terms captured CNS enrichment in duplications:
associative learning, NMDAR network, and GABAA receptor
complexes (see Supplemental Experimental Procedures).
Table 3. Enriched CNS Gene Sets, Deletions
Ngene p Padj OR (95% CI)
PSD-95 (core) 58 4.331011 1.73108 4.62 (2.85–7.8)
Abnormal neural plate morphology 23 2.13107 8.43105
Abnormal prepulse inhibition 74 3.33107 0.00013 1.94 (1.46–2.76)
Abnormal behavior 1,973 3.03106 0.0012 1.35 (1.2–1.54)
Abnormal fear/anxiety-related behavior 216 3.23106 0.0013 1.74 (1.38–2.23)
Abnormal CNS synaptic transmission 371 5.13106 0.002 1.56 (1.29–1.92)
Abnormal spatial working memory 38 5.63106 0.0022 4.94 (2.33–14.56)
Abnormal synaptic transmission 437 1.13105 0.0044 1.46 (1.23–1.74)
Abnormal emotion/affect behavior 369 1.13105 0.0044 1.45 (1.23–1.75)
Abnormal neuron differentiation 206 2.83105 0.011 2.51 (1.67–3.87)
Abnormal spatial learning 156 4.83105 0.019 1.66 (1.3–2.12)
Abnormal social/conspecific interaction 243 4.83105 0.019 1.56 (1.26–1.97)
Abnormal learning/memory/conditioning 424 7.33105 0.029 1.44 (1.21–1.73)
Abnormal miniature excitatory postsynaptic currents 62 0.0001 0.041 2.74 (1.57–4.95)
Cav2_channels 202 0.00017 0.068 1.85 (1.33–2.59)
Abnormal excitatory postsynaptic currents 69 0.00025 0.10 1.95 (1.31–2.93)
Abnormal axon extension 46 0.00027 0.11 5.68 (2.21–17.65)
Abnormal depression-related behavior 76 0.00033 0.13 3.69 (1.75–8.54)
ARC 25 0.00034 0.14 1.7 (1.24–2.33)
Abnormal excitatory postsynaptic potential 59 0.00067 0.27 4.2 (1.64–12.87)
GABAA 15 0.00068 0.27 2.43 (1.36–4.49)
Abnormal nervous system development 801 0.00073 0.29 1.43 (1.17–1.75)
Abnormal aggression-related behavior 63 0.00075 0.30 3.33 (1.64–7.24)
Abnormal response to novelty 152 0.00079 0.32 1.48 (1.18–1.87)
Abnormal sensory capabilities/reflexes/nociception 590 0.0008 0.32 1.39 (1.13–1.7)
CNS gene sets with Puncorrected < 0.001 in the analysis of deletions are listed along with number of genes in each set, Ngene; uncorrected (p) and
Bonferroni-corrected (Padj) p values for enrichment in case CNVs; and estimated odds ratios (OR). See also Tables S1 and S3.Once again there was no evidence of additional gene set enrich-
ment in eitherMPorGO annotations following Bonferroni correc-
tion (Tables S7 and S8).
Pathogenicity of Large CNVs Is Related to the Number of
CNS Genes Hit
Case CNVs > 100 kb were both larger (Pdel = 6.83 10
14, Pdup =
0.37) and overlap (‘‘hit’’) a greater number of genes (Pdel = 1.3 3
1016, Pdup = 3.43 10
5) than those found in controls. However,
even after conditioning on CNV size, the number of genes hit was
strongly and independently associated (Pdel = 1.03 10
5, Pdup =
2.93 105), whereas after conditioning on number of genes, the
effect of size was much weaker and was restricted to deletions
(Pdel = 0.0073, Pdup = 0.49). The number of genes hit is therefore
a better predictor of case-control status than CNV size.
We next investigated whether the relationship between num-
ber of genes hit and case-control status could be entirely attrib-
uted to genes within the disease-associated CNS annotations.
To test this, we combined all the CNS annotations that had a
Bonferroni-corrected p value < 0.05 to create a single associated
CNS set (CNSSZ). We did this separately for deletions and dupli-
cations. The number of CNSSZ genes hit by a CNV was a highly
significant predictor of case-control status for both deletions andduplications (Pdel = 1.13 10
21, Pdup = 1.73 10
12). Each was at
least five orders of magnitude more significant than the corre-
sponding analyses based on total number of genes hit (see pre-
vious paragraph). As expected this CNSSZ term remained highly
significant when conditioned on total number of genes hit in any
category (Pdel = 7.73 10
7, Pdup = 1.13 10
9), but the converse
was not the case; conditioning on CNSSZ there was little evi-
dence of any remaining effect of the total number of genes hit
by each CNV (Pdel = 0.21, Pdup = 0.053).
CNV Association Identifies Gene Sets Enriched for Rare,
De Novo NS Mutations
Finally, we investigated whether associated CNS gene sets were
also enriched in de novo non-synonymous (NS) mutations
(Fromer et al., 2014). To constrain both the number and size of
the gene sets tested, we collapsed the ‘‘minimal set’’ of terms
capturing most of the CNS enrichment signal (see analysis of
GO and MGI above) into a single gene set for each of our ana-
lyses (combined, deletion only, duplication only). Gene sets
capturing the CNS enrichments for deletions and duplications
were associated with de novo NSmutations observed in individ-
uals with schizophrenia. This was not entirely due to ARC and
NMDAR network genes (which we have previously describedNeuron 86, 1203–1214, June 3, 2015 ª2015 The Authors 1207
Table 4. Enriched CNS Gene Sets, Duplications
Ngene p Padj OR (95% CI)
Abnormal associative
learning
193 1.631010 6.23108 1.73 (1.46–2.08)
NMDAR network 59 2.53109 1.03106 3.09 (2.09–4.67)
Abnormal long-term
potentiation
145 1.13106 0.00044 1.65 (1.34–2.04)
Abnormal avoidance
learning behavior
56 1.63106 0.00066 1.89 (1.45–2.47)
Abnormal cued
conditioning behavior
68 1.43105 0.0055 2.02 (1.41–3)
GABAA 15 5.4310
5 0.022 2.8 (1.56–5.67)
Abnormal contextual
conditioning behavior
89 0.00011 0.045 1.68 (1.28–2.23)
Abnormal
consumption
behavior
442 0.00050 0.20 1.27 (1.1–1.46)
Abnormal temporal
memory
108 0.00052 0.21 1.56 (1.2–2.04)
Thin cerebral cortex 45 0.00060 0.24 1.94 (1.3–2.92)
CNS gene sets with Puncorrected < 0.001 in the analysis of duplications are
listed along with number of genes in each set, Ngene; uncorrected (p) and
Bonferroni-corrected (Padj) p values for enrichment in case CNVs; and
estimated odds ratios (OR). Note that while the NMDAR network was
analyzed prior to other terms in this table, here it is corrected for the
same number of tests as other terms for ease of comparison. See also
Tables S1 and S3.to be enriched for de novo NS mutations; Fromer et al., 2014)
(Table 5). No enrichment was found when the analysis was
repeated in a corresponding set of mutations from unaffected in-
dividuals (Table 5). When all 21 CNS terms with Pcorrected < 0.05
(Tables 2–4) were tested individually, over half were nominally
enriched for de novo NS mutations (cf. none for mutations
from controls). While none survive correction for multiple testing
(Table S9), this has to be interpreted in the context of the very
weak enrichment in schizophrenia for de novo NS mutations,
and therefore low power to robustly detect gene set enrichment.
These findings independently support the broader relevance of
the gene sets we have identified in the present study, but larger
studies of de novo mutations will be required for finer-scale
dissection.
DISCUSSION
We have performed a detailed, functionally informed analysis of
large, rare CNVs from 11,355 schizophrenia cases and 16,416
controls. The results provide strong, novel evidence implicating
disruption of inhibitory GABAergic modulation of neuronal
signaling in schizophrenia and robustly confirm, and extend,
the genetic evidence implicating disruption of excitatory gluta-
matergic signaling (Figure 1). It is clear, however, that these
neuronal complexes do not entirely account for the enrichment
of CNVs in cases given the independent enrichments seen in
behavioral and neurodevelopmental gene sets. This suggests
that subcellular processes beyond those currently ascribed1208 Neuron 86, 1203–1214, June 3, 2015 ª2015 The Authorsto GABAergic and glutamatergic complexes remain to be
identified.
We found no evidence that the pathogenic effects of CNVs
reflect biological processes other than those directly relevant
to brain function. This conclusion follows from the absence of
additional gene set enrichments after conditioning on the CNS
sets, and is further supported by the observation that the number
of genes hit by a CNV in the disease-associated CNS pathways
was a better predictor of whether a CNV occurred in a case or a
control than total number of genes hit. This contrasts with recent
findings based on common polymorphisms, where independent
enrichments were found in enhancer elements that were active in
both CNS and immune tissues (Schizophrenia Working Group of
the Psychiatric Genomics Consortium, 2014), although a more
recent analysis by that group suggests that most, if not all, of
the signal is captured by the CNS enhancers (http://biorxiv.
org/content/early/2015/01/23/014241).
While 11 CNV loci have been strongly associated with schizo-
phrenia to date (Rees et al., 2014b), our results indicate thatmore
associated CNVs remain to be identified. The association be-
tween number of genes hit and pathogenicity suggests that, in
many instances, looking for a single gene explanation for CNV
pathogenicity may not be fruitful. Instead it indicates that patho-
genicity depends upon the total burden of relevant genes hit by a
CNV, or that different single genes are implicated in different in-
dividuals depending upon their genetic and environmental
context—the larger the CNV, the greater the probability that a
critical pathway or process will be sufficiently impaired. It should
be noted that the presence of multiple hits in the same CNV does
not artificially inflate the significance of our enrichment tests, as
each CNV only contributes once to the analysis.
There were strong, independent associations in postsynaptic
complexes derived from glutamatergic synapses: NMDAR com-
plex (Husi and Grant, 2001; Husi et al., 2000; Pocklington et al.,
2006) genes were enriched in case duplications, while PSD-95
(Ferna´ndez et al., 2009) and to a lesser extent ARC complexes
(Kirov et al., 2012) were enriched in deletions. When these find-
ings are combined with existing evidence from de novo CNVs
(Kirov et al., 2012), from rare SNVs and indels (Fromer et al.,
2014; Purcell et al., 2014), and more recently from GWASs
and common alleles (Schizophrenia Working Group of the Psy-
chiatric Genomics Consortium, 2014), the relevance of altered
glutamatergic signaling to schizophrenia etiology and patho-
physiology seems to be beyond any reasonable doubt.
While models of schizophrenia based upon NMDAR hypo-
function have a long history (Olney and Farber, 1995), the genetic
data now indicate that the glutamatergic contribution to schizo-
phrenia encompasses a much wider range of cellular processes
converging upon synaptic information processing and plasticity
(Figure 1). This is clearly inconsistent with hypotheses in which
deficits in glutamatergic signaling primarily reflect disruption
via neuromodulatory pathways (Stephan et al., 2009). Genetic
evidence for disruption of neuromodulators is so far restricted
to dopamine, with a genome-wide significant GWAS signal local-
ized to DRD2 (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014). Both serotonergic 5-HT2C and
nicotinic a7 receptor complexes were tested here, and neither
was found to be strongly associated (Table S1).
Table 5. ‘‘Minimal’’ CNS Gene Sets, Enrichment for NS De Novo Rare Variants
Ngene De Novo SNV
N Mutation
p Padj
Minus ARC/NMDAR
Observed Expected Ngene p
Combined 1,991 schizophrenia 110 96.63 0.084 0.24 1,930 0.25
Deletion 287 27 13.96 0.0014 0.0042 255 0.011
Duplication 249 24 12.04 0.0015 0.0045 191 0.026
Combined 1,991 control 64 60.45 0.33 1 1,930 0.28
Deletion 287 10 8.81 0.39 1 255 0.24
Duplication 249 6 7.53 0.76 1 191 0.68
Gene sets capturing CNS enrichment in combined, deletion, and duplication analyses were tested for enrichment with rare, non-synonymous de novo
mutations from individuals with schizophrenia. Listed are number of genes in each gene set (Ngene); number of variants found within these genes
(Observed); number of variants expected (Expected); uncorrected and Bonferroni-corrected p values (p, Padj), where correction is for the three
gene sets tested; plus p values following removal of ARC and NMDAR genes (Minus ARC/NMDAR). Analysis was then repeated for NS de novo
rare variants identified in unaffected controls (same correction procedure). See also Table S9.We also find novel, independent evidence for disruption of
GABAA receptor complexes (Heller et al., 2012) in schizophrenia.
Deficits in GABAergic signaling have long been hypothesized to
contribute to schizophrenia pathophysiology alongside pertur-
bation of dopaminergic and glutamatergic systems (Carlsson,
1988; Lewis et al., 2012; Olney and Farber, 1995; Roberts,
1972). Evidence supporting a direct involvement of GABA has
as yet not been compelling, being drawn from imaging studies
and animal models of putative intermediate phenotypes, or
post-mortem expression studies in small samples where reverse
causality or confounding cannot be excluded (Inan et al., 2013).
Here we find case CNVs to be enriched for components of
GABAA receptor complexes (Tables 2–4), with conditional ana-
lyses revealing the GABAA association signal to be independent
of that seen for NMDAR complex genes. Our results indicate that
abnormalities in GABAergic signaling play a direct pathogenic
role in schizophrenia and cannot be entirely attributed to
secondary effects of NMDAR dysfunction (Laruelle et al., 2005;
Lewis and Gonzalez-Burgos, 2006).
GABAA receptor complex enrichment was strongest among
duplications, where the most highly associated genes were a5,
b3, and d receptor subunits (Table S10). The genes encoding
a5 and b3 subunits are found within the Angelman/Prader-Willi
locus, while the d subunit has been mapped to the critical region
for the 1p36 deletion syndrome: a relatively common CNV asso-
ciated with a range of neurodevelopmental outcomes (Battaglia
et al., 2008; Shapira et al., 1997; Windpassinger et al., 2002) that
has recently been identified as a candidate locus for schizo-
phrenia (Rees et al., 2014a). The remaining autosomal GABAA re-
ceptor genes largely cluster within two loci on chromosomes 4
and 5, neither of which displayed evidence of enrichment (Table
S10). The GABAA enrichment signal for deletions was driven by
NRXN1, which encodes for the presynaptic cell adhesion protein
neurexin 1, common to both GABAergic and glutamatergic
synapses.
Multiple GABAA receptor subtypes exist, each with a unique
set of functional properties and a distinct spatiotemporal expres-
sion profile (reviewed by Fritschy and Panzanelli, 2014). In
contrast to the b3 subunit, which is common to many receptor
subtypes, a5 and d subunits occur in distinct, mainly extrasynap-
tic populations of receptors responsible for tonic inhibition. Thisindicates that the contribution of GABAergic signaling to schizo-
phrenia may not be primarily synaptic, although the presence of
CNVs inNRXN1 andGHPN, encoding neurexin 1 and the synap-
tic GABA receptor scaffolding protein gephyrin (Table S10), sug-
gests that perturbation of synaptic GABAergic signaling may
also play a role.
Tonic inhibition in the hippocampus, a process to which both
a5- and d-containing GABAA receptors contribute (Glykys
et al., 2008), alters the induction of long-term potentiation (Martin
et al., 2010). Moreover, prolonged activation of NMDARs has
been shown to reduce cell surface expression of d-containing re-
ceptors (Joshi and Kapur, 2013). Thus, there are potential func-
tional connections between our findings of enrichment for CNVs
in GABAergic and postsynaptic glutamatergic complexes in
schizophrenia. At the behavioral level, perturbation of NMDAR
and tonic GABA signaling both lead to alterations in associative
learning (Bauer et al., 2002; Martin et al., 2010; Rodrigues et al.,
2001). This hierarchy of functionally related processes, from sub-
cellular complexes to behavioral learning via cellular signaling
and plasticity, encapsulates the elements of gene set enrichment
common to case duplications and deletions (Tables 2–4).
Our findings are consistent with a considerable body of non-
genetic literature; it is nearly 40 years since the cognitive deficits
seen in schizophrenia were first proposed to reflect dysfunc-
tional associative learning (Miller, 1976), with later hypotheses
suggesting perturbed synaptic plasticity as the source of this
dysfunction (Friston, 1998). Our identification of independent ge-
netic associations in glutamatergic andGABAergic complexes is
particularly relevant to proposals that alteration in the ratio of
excitatory to inhibitory transmission (E/I balance) underlies the
behavioral deficits seen in schizophrenia (reviewed by Kehrer
et al., 2008; see also Yizhar et al., 2011). Discussions typically
focus upon the oscillatory properties of neuronal networks,
fundamental to efficient information transfer and the coordina-
tion of neuronal assemblies (Buzsa´ki and Draguhn, 2004; Buz-
sa´ki and Watson, 2012). Deficits in gamma rhythms have been
reported in schizophrenia (reviewed by Uhlhaas and Singer,
2010), and while multiple mechanisms contribute to the genera-
tion of these rhythms (Bartos et al., 2007), deficits have primarily
been hypothesized to result from the altered firing of GABAergic
interneurons (Lewis and Gonzalez-Burgos, 2006; Uhlhaas andNeuron 86, 1203–1214, June 3, 2015 ª2015 The Authors 1209
Figure 1. Functional Interactions between Neuronal Complexes Implicated in Schizophrenia
Supporting and extending previous studies (Fromer et al., 2014; Kirov et al., 2012; Purcell et al., 2014), our analyses indicate a contribution to schizophrenia from
ARC, NMDAR network, PSD-95, and GABAA neuronal complexes. Although not strongly associated here, targets of the translational repressor FMRP have
previously been found to be enriched in CNVs and rare de novo small mutations in individuals with schizophrenia (Fromer et al., 2014; Purcell et al., 2014;
Szatkiewicz et al., 2014). This figure summarizes the relationship between these sets of molecules and their roles in synaptic signaling and plasticity.
(A) PSD-95 complexes are an important component of the postsynaptic scaffold at glutamatergic synapses, linking a wide range of channels and receptors
including NMDARs (top left). Calcium influx via the NMDAR drives multiple downstream pathways (red arrows): local signaling regulates induction of synaptic
potentiation, while activation of ARC transcription via signaling to the nucleus is required for the long-term maintenance of synaptic changes. Once transcribed,
mRNAs encoding ARC and other synaptic proteins are inactivated via association with FMRP and transported to synaptodendritic sites of protein synthesis.
Here, activity-dependent dissociation of FMRP releases transcripts from translational repression allowing protein synthesis and incorporation into active
synapses.
(B) NMDAR activation requires both presynaptic glutamate release and strong post-synaptic depolarization, which may be induced by the back-propagation of
action potentials. Influx of chloride ions via GABA receptors attenuates the dendritic transmission of excitation, inhibiting action potential generation and back-
propagation. Phasic firing of synaptic GABA receptors plays a key role in establishing neural oscillations, required for the coordination of distributed functional
networks. Tonic GABA receptors also modulate excitatory currents and oscillatory neuronal behavior, being responsive to local network activity via the overspill
of GABA from synaptic receptors and its release/uptake by glia (blue cell in A). For simplicity all receptors are shown acting upon a single neuron; in reality, their
interplay is distributed across multiple neuronal cell types, e.g., tonic GABA currents also modulating synaptic GABA release from interneurons.Singer, 2010). Interestingly, the frequency of hippocampal
gamma oscillations is sensitive to the balance between
NMDAR-dependent excitation and GABA d subunit-dependent
tonic inhibition of interneurons (Mann and Mody, 2010), linking
these hypotheses directly to our findings.
Although less discussed in relation to schizophrenia, E/I bal-
ance also plays a role in the development and maintenance of
stable perceptual and motor representations (reviewed by Car-
cea and Froemke, 2013). During early post-natal development
unbalanced excitatory input drives activity-dependent plasticity,
shaping emerging networks of synaptic connections in response
to the environment. As networks mature and inhibitory elements
are progressively integrated, E/I inputs become correlated mak-
ing internal representations resistant to further modification. In1210 Neuron 86, 1203–1214, June 3, 2015 ª2015 The Authorsthe adult brain, activation of neuromodulatory systems (including
acetylcholine, dopamine, and serotonin) can alter E/I balance, al-
lowing sensory circuits to again become sensitive to environ-
mental input. Unlike the experience-dependent modifications
that occur during development, plasticity in adult sensory cortex
is generally transient (see Carcea and Froemke, 2013). Genetic
associations potentially link the main elements of these pro-
cesses to schizophrenia: E/I signaling and synaptic plasticity
through our analyses, dopaminergic signaling via the DRD2
GWAS locus noted above (Schizophrenia Working Group of
the Psychiatric Genomics Consortium, 2014). Disruption of
such processes may potentially play a role in the developmental
trajectory of schizophrenia, or in the manifestation of transient
perceptual alterations during psychotic episodes.
In conclusion, our analyses support and extend previous
studies (Fromer et al., 2014; Kirov et al., 2012; Purcell et al.,
2014) indicating a contribution to schizophrenia from complexes
central to the induction (NMDAR) and maintenance (ARC)
of synaptic plasticity and provide strong novel evidence for
the involvement of inhibitory modulation (GABA) of synaptic
signaling (Figure 1). Perturbation of these processes is likely to
have a widespread impact on brain function, and only a subset
of genetic lesions within these systems may be compatible
with a schizophrenia phenotype. The identification of the mech-
anisms by which disruption of these processes by genetic
mutation leads to psychopathology will doubtless require exper-
imental studies in model systems of high construct validity. The
strength of genetic evidence converging on a plausible and
coherent set of biological processes provides firm foundations
upon which such studies can now proceed.
EXPERIMENTAL PROCEDURES
Samples, Genotyping, and CNV Quality Control
Case and control CNVs were derived from three samples: CLOZUK, the ISC,
and the MGS. A full description of these samples, the arrays they were gen-
otyped on, and CNV calling procedures can be found in the Supplemental
Experimental Procedures or in the original publications (International Schizo-
phrenia Consortium, 2008; Levinson et al., 2011; Rees et al., 2014a). Briefly,
CLOZUK samples were genotyped on several Illumina arrays. In order to limit
any bias in detecting specific CNVs between the CLOZUK cases and con-
trols, done on different arrays, for CNV calling we used only the 520,766
probes common to all these arrays. In the CLOZUK sample CNVs were called
with PennCNV (Wang et al., 2007). All MGS samples were genotyped on Af-
fymetrix 6.0 arrays, and approximately equal proportions of ISC cases and
controls were genotyped on either Affymetrix 6.0 or Affymetrix 5.0 arrays
(see Supplemental Experimental Procedures). In the MGS and ISC samples
CNVs were detected using Birdsuite (Korn et al., 2008). Only samples with
a European ancestry were retained for analysis. Rigorous quality control
was performed to remove low-quality samples (full details presented in
the Supplemental Experimental Procedures), resulting in 5,745 cases and
10,675 controls in CLOZUK, 2,214 cases and 2,556 controls in MGS, and
3,395 cases and 3,185 controls in ISC retained for analysis. Taking CNV calls
from samples which passed quality control in each study, CNVs were joined if
the distance separating them was less than 50% of their combined length.
CNVs were excluded if they overlapped low copy repeats by more than
50% of their length, or had a probe density < 1 probe/20 kb. CNVs with a fre-
quency > 1% or identified as false positives by an in silico median Z score
outlier method were also removed (Kirov et al., 2012). Z score validation
was not performed for the ISC study as we did not have access to the raw
intensity data. Following QC, genes overlapping CNVs were identified using
genomic locations for the appropriate build of the human genome: Build 35
of the human genome for ISC, Build 36 for MGS, and Build 37 for CLOZUK.
Studies were then collated, and CNVs < 100 kb in size and/or covered by < 15
probes were removed prior to analysis. Differences in genotyping chip, CNV
calling, and genome build between studies are controlled for in our enrich-
ment analyses through the ‘‘chip’’ and ‘‘study’’ covariates; while between-
study differences may reduce power to identify true positives, they do not
increase the rate of false positives. See Supplemental Experimental Proce-
dures for further details.
Gene Annotations
Proteomic studies used to derive subcellular terms are listed in Table S1. For
terms analyzed in Kirov et al. (2012), the processed gene sets analyzed in that
study were re-used here. Gene sets for all other subcellular terms were ex-
tracted from the relevant studies andmapped to human coding genes. GO an-
notations were taken from NCBI gene2go (ftp://ftp.ncbi.nih.gov/DATA), using
Homo sapiens annotations only. MP ontology and gene annotations weredownloaded from the Mouse Genome Informatics (MGI) online resource
(http://www.informatics.jax.org). Genes were mapped to human using the
file HOM_MouseHumanSequence.rpt, also downloaded fromMGI. For further
details see Supplemental Experimental Procedures.
Enrichment Test for Individual Gene Sets
For each gene set, the numbers of genes ‘‘hit’’ by case and control CNVs
were compared; a gene was counted as being hit by a CNV if the CNV over-
lapped any part of its length. To overcome biases related to gene and
CNV size, and to control for differences between studies and genotyping
chips, the following logistic regression models were fitted to the combined
set of CNVs:
(a) logit (pr(case)) = study + chip + CNV size + total number of genes hit
(b) logit (pr(case)) = study + chip + CNV size + total number of genes hit +
number of genes hit in gene set
Comparing the change in deviance between models (a) and (b), a one-sided
test for an excess of genes in the gene set being hit by case CNVs was
performed. For further details and a full description of the approach taken
for multiple testing correction (outlined in the main text), see Supplemental
Experimental Procedures.
Permutation Test for General Enrichment of CNS Gene Sets
Case-control status was permuted 1,000 times, status being shuffled between
CNVs from the same study and genotyping chip (‘‘Affymetrix 5.0,’’ ‘‘Affymetrix
6.0,’’ or ‘‘Illumina’’). Enrichment analyses were performed in each permuted
dataset; the proportion of datasets in which the number of terms with p <
Pthr equaled or exceeded that of the true data being used as the empirical p
value for an excess of associated terms at the threshold Pthr.
Enrichment beyond CNS-Related Terms
From CNS gene sets with Pcorrected < 0.05, a subset was identified that
captured the association signal in all other terms. GO and MGI terms were
then analyzed using the enrichment test outlined above, but with this ‘‘mini-
mal’’ set of terms added as covariates to the regression models (see main
text and Supplemental Experimental Procedures).
Removing Signal from Known Loci
To investigate whether gene set enrichment was solely driven by CNVs at loci
well supported by current data (Table S2), we removed all CNVs overlapping
these loci and re-ran the enrichment analysis as above. See Supplemental
Experimental Procedures for further details.
Single Gene Enrichment Analysis
This was performed in an identical manner to gene set enrichment analysis, but
with each ‘‘gene set’’ here comprising a single gene. The term ‘‘number of
genes hit in gene set’’ in model (b) thus becomes a binary variable.
CNV Size and Number of Genes Hit as Predictors of Case-Control
Status
CNV size and number of genes hit (either total or CNSSZ) were regressed
against CNV case-control status under a logistic regressionmodel. Covariates
were included for study and genotyping chip (as in enrichment test, above).
See Supplemental Experimental Procedures for further details.
De Novo Rare Variant Analysis
NS de novo variants found in individuals with schizophrenia were taken from
Fromer et al. (2014), consisting of variants identified in four separate studies
(Fromer et al., 2014; Girard et al., 2011; Gulsuner et al., 2013; Xu et al.,
2012). These were analyzed for gene set enrichment using the dnenrich
software (Fromer et al., 2014) (http://bitbucket.org/statgen/dnenrich). NS de
novo variants found in unaffected individuals were also taken from Fromer
et al. (2014) and analyzed in an identical fashion. These consisted of healthy
controls and unaffected siblings collated from six separate studies (Gulsuner
et al., 2013; Iossifov et al., 2012; O’Roak et al., 2012; Rauch et al., 2012;
Sanders et al., 2012; Xu et al., 2012).Neuron 86, 1203–1214, June 3, 2015 ª2015 The Authors 1211
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